We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Candidate Cancer Drug Blocks Growth and Reverses Drug Resistance

By LabMedica International staff writers
Posted on 09 Oct 2018
A candidate drug for treatment of pancreatic cancer was shown to slow growth and spread of the disease in cell cultures and reverse drug resistance in preclinical animal models.

Growth, progression, and drug resistance of pancreatic ductal adenocarcinomas (PDACs) have been associated with increased levels and activity of the enzymes glycogen synthase kinase 3 beta (GSK3B) and histone deacetylases (HCACs). More...
GSK-3B stimulates proliferation and resistance to apoptosis in cancer cells while HDAC inhibits epithelial cells. A drug that inhibits these two enzymes should simultaneously affect proliferation and metastasis.

The drug candidate, Metavert, is a small molecular dual inhibitor that blocks two pro-cancer pathways through two linked moieties that target GSK3B and HDAC. In a study published in the August 22, 2018, online edition of the journal Gastroenterology, investigators at Cedars-Sinai Medical Center (Los Angeles, CA, USA) - who hold a patent on the drug - tested its effects in pancreatic cancer cells and mice with pancreatic tumors.

The investigators tested the ability of Metavert to bind GSK3B and HDACs in various cell lines using surface plasmon resonance. Plasmon resonance is a phenomenon that occurs when light is reflected off thin metal films, which may be used to measure interaction of biomolecules on the surface. An electron charge density wave arises at the surface of the film when light is reflected at the film under specific conditions. A fraction of the light energy incident at a defined angle can interact with the delocalized electrons in the metal film (plasmon) thus reducing the reflected light intensity. The angle of incidence at which this occurs is influenced by the refractive index close to the backside of the metal film, to which target molecules are immobilized. If ligands in a mobile phase running along a flow cell bind to the surface molecules, the local refractive index changes in proportion to the mass being immobilized. This can be monitored in real time by detecting changes in the intensity of the reflected light.

Treated cells were analyzed for apoptosis and migration and by immunoblotting, immunofluorescence, and real-time PCR. Normal mice were given injections of Metavert or vehicle (control). B6.129J mice with tumors grown from UN-KPC961-Luc cells were given injections of Metavert or vehicle. Tumors and metastases were counted and pancreata were analyzed by immunohistochemistry. Glucose metabolism was measured using 13C-glucose tracer and mass spectroscopy and flow cytometry.

Results revealed that Metavert significantly reduced survival of PDAC cells but not non-transformed cells. The drug reduced markers of the epithelial to mesenchymal transition and stem cells in PDAC cell lines. Cells incubated with Metavert in combination with irradiation and the chemotherapeutic agent paclitaxel or gemcitabine had reduced survival compared to cells incubated with either agent alone. Metavert increased killing of drug-resistant PDAC cells by paclitaxel and gemcitabine. In addition, PDAC cells incubated with Metavert acquired normalized glucose metabolism.

Administration of Metavert (alone or in combination with gemcitibine) to mice with syngeneic tumors significantly increased their survival times, slowed tumor growth, prevented tumor metastasis, decreased tumor infiltration by tumor-associated macrophages, and decreased blood levels of cytokines.

"This is an exciting step toward improving survival rates in pancreatic cancer patients," said first author Dr. Mouad Edderkaoui, assistant professor of medicine and biomedical sciences at Cedars-Sinai Medical Center. "If the results are confirmed in humans, we could have a drug with the potential to significantly extend the lives of patients with pancreatic ductal adenocarcinoma (PDAC), which is very difficult to treat."

Related Links:
Cedars-Sinai Medical Center

Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.